CDC ad­vi­sors broad­en RSV vac­cine rec­om­men­da­tions to at-risk adults in their 50s

A CDC ad­vi­so­ry pan­el vot­ed to rec­om­mend RSV vac­cines for at-risk adults aged 50 to 59, a sought-af­ter ex­pan­sion by vac­cine mak­ers who are try­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA